Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma Co's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 50.89.
Wuhan YZY Biopharma Co's Days Inventory for the
six
months ended in Dec. 2025 was 23.75.
Wuhan YZY Biopharma Co's Days Payable for the
six
months ended in Dec. 2025 was 28.03.
Therefore, Wuhan YZY Biopharma Co's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 46.61.
Wuhan YZY Biopharma Co (HKSE:02496) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Wuhan YZY Biopharma Co Cash Conversion Cycle Related Terms
Wuhan YZY Biopharma Co Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Wuhan YZY Biopharma Co's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co Cash Conversion Cycle Chart
HKSE:02496 vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's Cash Conversion Cycle falls into.
Wuhan YZY Biopharma Co Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Wuhan YZY Biopharma Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) has a Cash Conversion Cycle of 46.61 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Wuhan YZY Biopharma Co and its competitors.
Is Wuhan YZY Biopharma Co's Cash Conversion Cycle too high?
Wuhan YZY Biopharma Co's current Cash Conversion Cycle is 46.61. The Biotechnology industry median Cash Conversion Cycle is 103.45. Wuhan YZY Biopharma Co's value of 46.61 is 54.9% below this industry median.
How does Wuhan YZY Biopharma Co's Cash Conversion Cycle compare to VRTX and REGN?
Wuhan YZY Biopharma Co's Cash Conversion Cycle of 46.61 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.45. Wuhan YZY Biopharma Co's value of 46.61 is 54.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.45, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuhan YZY Biopharma Co's current Cash Conversion Cycle of 46.61 is 54.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Wuhan YZY Biopharma Co and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan YZY Biopharma Co's current Cash Conversion Cycle is 46.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Cash Conversion Cycle of 46.61. The current Cash Conversion Cycle is 46.61 and 54.9% below the Biotechnology industry median of 103.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Cash Conversion Cycle is 46.61 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
